MYOFIBROMA IN PEDIATRIC PATIENTS: DIAGNOSIS AND TREATMENT OF A RARE LESION

Abstract

Myofibroma is a rare benign soft tissue neoplasm characterized by a large, growing, destructive mass. It shows predilection for the head and neck regions, the mandible being the most common oral location. Its biological behavior is unpredictable, presenting malignant lesions as differential diagnosis, and it is usually treated by surgical excision, despite reports of spontaneous regression. Patient E.T.S., 4 years old and female, was referred to our service with a chief complaint of showing "a lump in the chin." A swelling in the left mandible angle that was hard to palpation and associated to pain complaint with evolution of 6 months was observed. An incisional biopsy was performed, and the results revealed the diagnosis of myofibroma. The patient was referred to pediatrics for evaluation, the result being negative for others myofibromas. The treatment consisted of submandibular extraoral access for the excision of the tumor. The patient has 4 years of follow-up without signs of recurrence. Myofibroma is a rare benign soft tissue neoplasm characterized by a large, growing, destructive mass. It shows predilection for the head and neck regions, the mandible being the most common oral location. Its biological behavior is unpredictable, presenting malignant lesions as differential diagnosis, and it is usually treated by surgical excision, despite reports of spontaneous regression. Patient E.T.S., 4 years old and female, was referred to our service with a chief complaint of showing "a lump in the chin." A swelling in the left mandible angle that was hard to palpation and associated to pain complaint with evolution of 6 months was observed. An incisional biopsy was performed, and the results revealed the diagnosis of myofibroma. The patient was referred to pediatrics for evaluation, the result being negative for others myofibromas. The treatment consisted of submandibular extraoral access for the excision of the tumor. The patient has 4 years of follow-up without signs of recurrence.